<DOC>
	<DOCNO>NCT02296255</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness vaccination 25-year old woman time first access cervical cancer screening , understand impact vaccination screen activity ; evaluate immune response follow vaccination ; study dynamic infection vaccination , include possible change frequency non-vaccine HPV type , evaluate cytological abnormality reduction vaccinate woman assess HPV test urine sample could useful non-invasive method monitor HPV status young woman .</brief_summary>
	<brief_title>Effect HPV Vaccination Women Aged 25 Years</brief_title>
	<detailed_description>The present trial , fund Istituto Toscano Tumori , start 2010 directed woman age 25 ( birth cohort 1985 1986 ) , resident province Florence target screen program . After receive approval Ethics Committee Local Health Unit Florence , woman invite invitation letter contain clear description study . All woman comply invitation ask fill inform consent document . Women randomize 1:2 Experimental Arm Control Arm . At enrollment , woman Experimental Arm , collection cervical sample ( Pap-test HPV test ) , blood sample ( HPV antibody test serum vaccination ) one first void urine sample ( HPV test ) , receive free vaccination Cervarix® ( vaccine HPV 16 18 , 3 dos schedule ) . Women Control Arm receive usual care , i.e . collection cervical sample Pap test . All woman sign informed consent enrol regardless sexually active . For virgo woman cervical sample collect . At second round screening ( 30 month since enrollment ) , woman Arms ask collect cervical sample ( Pap-test HPV test ) new blood sample HPV antibody test collected woman enrol Experimental Arm . Women normal cytology Control Arm woman HPV-negative result normal cytology Experimental Arm , receive recommendation mail repeat screen test 3 year . Women abnormal Pap test ( Atypical Squamous Cells Undetermined Significance severe , ASC-US+ ) refer immediate colposcopy Cancer Prevention Research Insitute . Women normal cytology HPV positive call one year repeat HPV test Pap test . If HPV Pap test negative , woman repeat test 30 month enrolment . Otherwise HPV test remain positive and/or cytology abnormality detect woman refer colposcopy : colposcopy n't reveal high grade lesion ( ≤ CIN2 ) woman repeat HPV Pap test 30 month enrollment , colposcopy reveal final histological diagnosis CIN2+ lesion , woman recommend excisional treatment ( study control group ) . The presence high risk ( HR ) HPVs evaluate Hybrid Capture 2 ( Qiagen , Gaithersburg , USA ) use probe B detection 12 high risk HPV type : 16 , 18 , 31 , 33 , 35 , 39 , 45 , 51 , 52 , 56 , 58 , 59 ( Group 1 ) 1 `` probably carcinogenic human '' type HPV 68 ( Group 2 ) . HPV genotyping perform INNO-LiPA Genotyping Extra allow identification 28 different HPV type L1 region HPV genome , identifies know HPV high-risk type ( Group 1 ) 16 , 18 , 31 , 33 , 35 , 39 , 45 , 51 , 52 , 56 , 58 , 59 ; `` probably carcinogenic human '' ( Group 2A ) HPV68 ; `` possibly carcinogenic '' HPV 26 , 53 , 66 , 69 , 70 , 73 , 82 ( Group 2B ) `` classified carcinogenicity human '' ( Group 3 ) ( 6 , 11 ) ; HPV type : 40 , 43 , 44 , 54 , 71 , 74 . HPV antibody test perform establish validated HPV serology method base Luminex technology heparin coat bead pseudovirions ( PsVs ) 17 HPV type belong alpha specie : 3 , 6 , 11 , 16 , 18 , 31 , 32 ,33 , 35 , 39 , 45 , 52 , 56 , 58 , 59 , 68 , 73 , four HPV type belong beta specie : 5 , 15 , 38 , 76 .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>resident Florence invite first time cervical cancer screen Florence age 25 year</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>cervical cancer screen</keyword>
	<keyword>young woman vaccination</keyword>
	<keyword>impact HPV vaccination screen</keyword>
</DOC>